{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:19Z","timestamp":1790916979264,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20171-9","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:31:24Z","timestamp":1783344684000},"page":"9630-9631","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ASO Author Reflections: Does the Axilla Still Matter? Rethinking Nodal Staging in the Era of CDK4\/6 Inhibition"],"prefix":"10.1245","volume":"33","author":[{"given":"Austin D.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"20171_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","volume":"37","author":"S Johnston","year":"2025","unstructured":"Johnston S, Martin M, O\u2019Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2025;37:155\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005.","journal-title":"Ann Oncol."},{"key":"20171_CR2","doi-asserted-by":"publisher","first-page":"105858","DOI":"10.1016\/j.esmoop.2025.105858","volume":"10","author":"J Crown","year":"2025","unstructured":"Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10:105858. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105858.","journal-title":"ESMO Open."},{"issue":"7","key":"20171_CR3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/CNCR.35136","volume":"130","author":"AD Williams","year":"2024","unstructured":"Williams AD, Ruth K, Shaikh SS, et al. Should patients with hormone receptor\u2013positive, HER2\u2013negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib? Cancer. 2024;130(7):1052\u201360. https:\/\/doi.org\/10.1002\/CNCR.35136.","journal-title":"Cancer."},{"key":"20171_CR4","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/S1470-2045(24)00350-4","volume":"25","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Appelgren M, Szulkin R, et al. Completion axillary lymph node dissection for the identification of pN2\u20133 status as an indication for adjuvant CDK4\/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial. Lancet Oncol. 2024;25:1222\u201330. https:\/\/doi.org\/10.1016\/S1470-2045(24)00350-4.","journal-title":"Lancet Oncol."},{"key":"20171_CR5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-026-20131-3","author":"AD Williams","year":"2026","unstructured":"Williams AD, Lyons W, Taylor L, et al. Role of sentinel node surgery in identifying candidates for adjuvant CDK4\/6 inhibitors: implications of choosing wisely and ASCO omission criteria. Ann Surg Oncol. 2026. https:\/\/doi.org\/10.1245\/s10434-026-20131-3.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20171-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20171-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20171-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:13Z","timestamp":1790916673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20171-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":5,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20171"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20171-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Austin D. Williams is a consultant for Elucent Medical (Eden Prairie, MN, USA).","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}